Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$17.51 - $23.37 $61,845 - $82,542
3,532 Added 17.54%
23,670 $465,000
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $253,537 - $378,594
20,138 New
20,138 $352,000
Q1 2022

May 16, 2022

SELL
$12.02 - $16.69 $130,753 - $181,553
-10,878 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$10.69 - $16.83 $116,285 - $183,076
10,878 New
10,878 $177,000
Q2 2021

Aug 16, 2021

SELL
$13.6 - $18.98 $325,774 - $454,646
-23,954 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$14.17 - $19.11 $339,428 - $457,760
23,954 New
23,954 $372,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.